% | $
Quotes you view appear here for quick access.

Medivation, Inc. Message Board

  • denoforest denoforest Apr 12, 2013 1:49 PM Flag

    This is not a $9 B drug - target on MDVN is $12

    if ARN509 hits the market next year and $6 if it is approved this year. MDVN has gone fro $0.70 to $116.00 before the 2 for 1 split. It was $42 a week ago before the pop. Since MDVN doesn't get even half the profits, and lost the patent fight, it is not selling well now because it is overpriced Xtandi, a big mistake in a competitive field.

62.43-0.20(-0.32%)2:11 PMEDT